Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System

Author(s): Luc Bertrand, Madhavan Nair, Michal Toborek.

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 35 , 2016

Abstract:

Recent decades mark a great progress in the treatment of HIV infection. What was once a deadly disease is now a chronic infection. However, HIV-infected patients are prone to develop comorbidities, which severely affect their daily functions. For example, a large population of patients develop a variety of neurological and cognitive complications, called HIV associated neurological disorders (HAND). Despite efficient repression of viral replication in the periphery, evidence shows that the virus can remain active in the central nervous system (CNS). This low level of replication is believed to result in a progression of neurocognitive dysfunction in infected individuals. Insufficient viral inhibition in the brain results from the inability of several treatment drugs in crossing the blood-brain barrier (BBB) and reaching therapeutic concentrations in the CNS. The current manuscript discusses several strategies that are being developed to enable therapeutics to cross the BBB, including bypassing BBB, inhibition of efflux transporters, the use of active transporters present at the BBB, and nanotechnology. The increased concentration of therapeutics in the CNS is desirable to prevent viral replication; however, potential side effects of anti-retroviral drugs need also to be taken into consideration.

Keywords: HIV, Blood brain barrier, anti-retroviral drugs, central nervous system, viral reservoir, nanoparticles.

Rights & PermissionsPrintExport

Article Details

VOLUME: 22
ISSUE: 35
Year: 2016
Page: [5477 - 5486]
Pages: 10
DOI: 10.2174/1381612822666160726113001
Price: $58

Article Metrics

PDF: 31
HTML: 3
EPUB: 1
PRC: 1